Nörokütan Hastalıkların Göz Bulguları ve Yönetimi
Özet
Nörokütanöz sendromlar (fakomatozlar), nöral krest hücrelerinin embriyonik gelişim bozukluklarına bağlı olarak cilt ve sinir sisteminde hamartamöz lezyonlarla seyreden konjenital hastalıklardır. Nörofibromatozis, tuberoz skleroz, Sturge-Weber sendromu, Von Hippel-Lindau hastalığı ve ataksi telenjiektazi gibi bu grup hastalıklar, Lisch nodülleri, optik gliomlar, retinal astrositik hamartomlar, glokom ve konjonktival telenjiektaziler gibi karakteristik oküler bulgular sergiler. Tanı genellikle kapsamlı oftalmolojik muayene, biyomikroskopi ve ileri görüntüleme teknikleriyle konulurken, tedavi yaklaşımları tümörlerin yerleşimi, görme fonksiyonu üzerindeki etkileri ve hastalığın spesifik komplikasyonlarına göre düzenlenir. Erken tanı ve düzenli oftalmolojik takip, bu sistemik hastalıkların vizyon tehdit edici komplikasyonlarının yönetimi açısından kritik öneme sahiptir.
Neurocutaneous syndromes (phakomatoses) are a group of congenital disorders characterized by hamartomatous lesions in the skin and nervous system, resulting from abnormalities in neural crest cell development. This group, including neurofibromatosis, tuberous sclerosis, Sturge-Weber syndrome, Von Hippel-Lindau disease, and ataxia-telangiectasia, presents with characteristic ocular findings such as Lisch nodules, optic gliomas, retinal astrocytic hamartomas, glaucoma, and conjunctival telangiectasias. Diagnosis typically involves comprehensive ophthalmological examination, biomicroscopy, and advanced imaging techniques, while treatment strategies are tailored based on tumor location, impact on visual function, and specific disease complications. Early diagnosis and regular ophthalmological follow-up are critical for managing the vision-threatening complications of these systemic diseases.
Referanslar
Sarnat HB, Flores-Sarnat L. Embryology of the neural crest: its inductive role in the neurocutaneous syndromes. J Child Neurol. 2005;20(8):637-43.
Lubs ML, Bauer MS, Formas ME, et al. Lisch nodules in neurofibromatosis type 1. N Engl J Med. 1991;324(18):1264-6.
Kinori M, Hodgson N, Zeid JL. Ophthalmic manifestations in neurofibromatosis type 1. Surv Ophthalmol. 2018;63(4):518-33.
Avery RA, Mansoor A, Idrees R, et al. Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1. Neurology. 2016;87(23):2403-7.
Greenwald MJ, Weiss A. Ocular manifestations of the neurocutaneous syndromes. Pediatr Dermatol. 1984;2(2):98-117.
Ashwini Kini M, Sydney Wendt. Ocular Manifestations of Phakomatoses (Neurocutaneous Syndromes) [updated April 8, 2021.27.04.2021]. Available from: https://eyewiki.aao.org/Ocular_Manifestations_of_Phakomatoses_(Neurocutaneous_Syndromes)#:~:text=Other%20common%20findings%20include%20cataracts,characterized%20by%20bilateral%20vestibular%20schwannomas.
Parrozzani R, Clementi M, Kotsafti O, et al. Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Vis Sci. 2013;54(13):8112-8.
Chernoff KA, Schaffer JV. Cutaneous and ocular manifestations of neurocutaneous syndromes. Clin Dermatol. 2016;34(2):183-204.
Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81-8.
Packer RJ, Gutmann DH, Rubenstein A, et al. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology. 2002;58(10):1461-70.
Dombi E, Baldwin A, Marcus LJ, et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016;375(26):2550-60.
Randle SC. Tuberous Sclerosis Complex: A Review. Pediatr Ann. 2017;46(4):e166-e71.
Rowley SA, O'Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol. 2001;85(4):420-3.
Abdolrahimzadeh S, Plateroti AM, Recupero SM, et al. An Update on the Ophthalmologic Features in the Phakomatoses. J Ophthalmol. 2016;2016:3043026.
Mantelli F, Bruscolini A, La Cava M, et al. Ocular manifestations of Sturge-Weber syndrome: pathogenesis, diagnosis, and management. Clin Ophthalmol. 2016;10:871-8.
Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059-67.
Wong WT, Liang KJ, Hammel K, et al. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology. 2008;115(11):1957-64.
Farr AK, Shalev B, Crawford TO, et al. Ocular manifestations of ataxia-telangiectasia. Am J Ophthalmol. 2002;134(6):891-6.
Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):159.
Shaikh AG, Marti S, Tarnutzer AA, et al. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia. J Neurol. 2013;260(11):2728-35.
